Understand the source comparison
Peptide Comparison: Mechanisms and Clinical Evidence
KPV (Lysine-Proline-Valine) NF-κB inhibition; reduces pro-inflammatory cytokine transcription (TNF-α, IL-6, IL-8) Mast cell activation and neutrophil chemotaxis Inflammation Research 2019: 52% reduction in IL-6 secretion at 10μM 0.01–0.1% topical; 5–10mg for r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- KPV (Lysine-Proline-Valine)
- NF-κB inhibition; reduces pro-inflammatory cytokine transcription (TNF-α, IL-6, IL-8)
- Mast cell activation and neutrophil chemotaxis
- Inflammation Research 2019: 52% reduction in IL-6 secretion at 10μM
- 0.01–0.1% topical; 5–10mg for research reconstitution
- Best peptide for acute inflammatory flares; targets the immune cascade directly
- GHK-Cu (Copper Peptide)
- Stimulates TGF-β, collagen synthesis, filaggrin expression; chelates copper for MMP activity
- Barrier dysfunction and impaired wound healing
- Seoul National University: 22% TEWL reduction, 18% hydration increase over 8 weeks at 0.1%
- 0.05–0.2% topical
- Best for chronic barrier repair; addresses the structural vulnerability that enables recurrent flares
- Thymosin Beta-4
- Actin polymerization regulation; accelerates re-epithelialization; reduces mast cell degranulation
- Chronic inflammation and epithelial repair
- Dermatologic Therapy: 34% reduction in subjective erythema, 28% reduction in physician-assessed inflammation over 12 weeks
- 0.001–0.01% topical
- Best for long-term tissue remodeling; reduces mast cell density and inflammatory persistence
- LL-37 Inhibitory Peptides (experimental)
- Block LL-37 receptor binding; prevent downstream inflammatory cascade
- Cathelicidin overproduction
- Preclinical only; Journal of Investigative Dermatology 2018 in-vitro data shows receptor blockade reduces keratinocyte IL-8 by 61%
- Not commercially available
- Mechanistically ideal but not yet clinically validated; future therapeutic target